

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Ibrutinib for treating relapsed or refractory mantle cell lymphoma [ID753]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

No issues were identified during the scoping process.

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

The committee noted the potential equality issue raised by the company and patient groups that ibrutinib would offer an alternative to less effective but better tolerated chemotherapy agents for older or frailer people. It also noted the issue raised that oral administration allows an effective treatment option for people without access or transport to an infusion unit and significantly reduces multiple hospital visits. The committee acknowledged that access to ibrutinib may enhance treatment in these groups of people, but it was unable to recommend ibrutinib because it could not be considered a cost-effective use of NHS resources.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No other equality issues were identified by the committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Not applicable, the technology is not recommended.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

None have been identified.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

The committee's consideration of equality issues have been described in section 4.15 of the appraisal consultation document

Approved by Associate Director (name):Janet Robertson.....

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No additional issues were raised during the consultation period

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No, the recommendations do not make it more difficult in practice for a specific group to access the technology compared with other groups.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No, there is no potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The committee's consideration of equality issues have been described in section 4.17 of the final appraisal determination.

Approved by Associate Director (name):Janet Robertson...

Date: 21 November 2017